Betamethasone Dipropionate (Teligent) – impurity issue (2021)
Class III: A situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences
Class III recall indicates unlikely adverse health consequences.
This AI-generated summary is provided for general informational purposes only and is derived from publicly available recall notices. It supplements but does not replace official agency classifications or safety instructions.
Check Your Product
According to the U.S. Food and Drug Administration (FDA)
Product
Betamethasone Dipropionate Ointment USP, 0.05% (Augmented), packaged in 50 grams tubes, Manufactured by: Teligent Pharma, Inc. Buena, New Jersey 08310, NDC 52565-019-51
Brand
Teligent Pharma, Inc.
Lot Codes / Batch Numbers
Lot #: 14297, Exp 9/2021, 15757, Exp 6/2022, 15840, Exp 7/2022, 15970, Exp 9/2022, 15993, Exp 9/2022
Products Sold
Lot #: 14297, Exp 9/2021; 15757, Exp 6/2022; 15840, Exp 7/2022; 15970, Exp 9/2022; 15993, Exp 9/2022
Teligent Pharma, Inc. is recalling Betamethasone Dipropionate Ointment USP, 0.05% (Augmented), packaged in 50 grams tubes, Manufactured due to Failed Impurities/ Degradation Specifications - OOS for know impurity Betamethasone 17- propionate.. This is a Class I recall, indicating a high risk of serious health consequences. Based on FDA drug enforcement report.
Summary derived from FDA notice
Reason for Recall
As stated by FDA
Failed Impurities/ Degradation Specifications - OOS for know impurity Betamethasone 17- propionate.
Recommended Action
Per FDA guidance
Consumers should stop using the product and contact the recalling firm, their healthcare provider, or return it to the place of purchase.
Verify this information on the official source
For complete details and official instructions, check the U.S. Food and Drug Administration (FDA) directly.
View official FDA recall noticePage updated: Jan 7, 2026